<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557046</url>
  </required_header>
  <id_info>
    <org_study_id>S-CLIN-PROT-00032</org_study_id>
    <nct_id>NCT04557046</nct_id>
  </id_info>
  <brief_title>Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 Ag Test at Point of Care Testing Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LumiraDx UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LumiraDx UK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference
      method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi-center study. One (1) reference laboratory and
      approximately six (6) geographically diverse POC (Point of Care) locations (e.g. physician
      office laboratories, urgent cares, emergency departments, outpatient clinics, drive through
      testing sites or research centers) in the U.S. will participate in the study. Testing in the
      reference laboratory will be performed by trained laboratory personnel. Testing at the POC
      sites will be performed by non-laboratory health professionals who are representative of
      typical intended use operators (e.g. nurses, physician assistants, medical assistants, etc.).
      Each site will have a minimum of one (1) untrained intended use operator who will perform
      testing under this protocol.

      A subject's participation in this study will consist of a single visit. Following completion
      of the informed consent process and a review of Inclusion/Exclusion criteria to determine
      eligibility, each subject will receive a unique study identification number.

      Subjects will have nasopharyngeal or nasal or throat swabs collected. Capillary blood may be
      collected alongside nasal swabs. Saliva samples may also be collected. Specimens will be
      obtained from each subject enrolled using standard collection methods.

      The LumiraDx SARS-CoV-2 Ag Test will be performed at POC sites by intended use operators
      (e.g. nurses, physician assistants, medical assistants, etc.). Each site will have a minimum
      of one (1) untrained intended use operator who will perform testing under this protocol.

      The LumiraDx SARS-CoV-2 Ag Test will be performed at the site on the same day as the date of
      collection using one swab for each subject enrolled. A central laboratory will perform
      reference testing.

      Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) will be estimated for
      the LumiraDx SARS-CoV-2 Ag Test results as compared with the reference Test.

      A minimum of thirty (30) positive SARS-CoV-2 are required, but it is likely because of the
      prevalence of SARS-CoV-2 in the population, that a greater number of negatives will be
      obtained during the prospective collection of positive samples; therefore, approximately
      four-hundred (400) subjects will be enrolled. A minimum of thirty (30) negative samples are
      required.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subject are asked to provide nasal swab or nasopharyngeal swab and saliva samples</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Evaluation</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluation of performance of the device versus a reference method using standard qualitative comparison techniques (Percent Agreement)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group A: Sample Collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasal Swab and Saliva Sample Collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Sample Collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Sample Collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasal Swab, Throat Swab and Saliva Sample Collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Sample Collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasopharyngeal Swab and Saliva Sample Collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: Sample Collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nasal swab</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal Swab</intervention_name>
    <description>Collection of one more nasal swabs</description>
    <arm_group_label>Group A: Sample Collection</arm_group_label>
    <arm_group_label>Group B: Sample Collection</arm_group_label>
    <arm_group_label>Group C: Sample Collection</arm_group_label>
    <arm_group_label>Group E: Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasopharyngeal swab</intervention_name>
    <description>Collection of one more nasopharyngeal swabs</description>
    <arm_group_label>Group D: Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Throat swab</intervention_name>
    <description>Collection of one more throat swabs</description>
    <arm_group_label>Group C: Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fingerstick</intervention_name>
    <description>Collection of capillary blood from one or more fingersticks</description>
    <arm_group_label>Group B: Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Saliva specimen</intervention_name>
    <description>Collection of free drool</description>
    <arm_group_label>Group A: Sample Collection</arm_group_label>
    <arm_group_label>Group B: Sample Collection</arm_group_label>
    <arm_group_label>Group C: Sample Collection</arm_group_label>
    <arm_group_label>Group D: Sample Collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. The subject may be of any age and either sex.

          -  2. Preliminary assessment of the subject by the Investigator/designee should be
             suggestive of COVID-19 at the time of the study visit. The subject must present as
             symptomatic, meaning they have exhibited one or more of the following signs and
             symptoms for eligibility: fever, cough, shortness of breath, difficulty breathing,
             muscle pain, headache, sore throat, chills, repeated shaking with chills, new loss of
             taste or smell. The onset of these symptoms will be recorded.

        or The subject must have a documented SARS-CoV-2 PCR test in the past 48 hours.

          -  3. Written informed consent must be obtained prior to study enrollment.

               1. A subject who is eighteen (18) years or older must be willing to give written
                  informed consent and must agree to comply with study procedures.

               2. The Legal Guardian or Legal Authorized Representative of a subject who is under
                  the age of eighteen (18) must give written informed consent and agree to comply
                  with study procedures. Active written assent should be obtained from children of
                  appropriate intellectual age (as defined by the IRB).

        Exclusion Criteria:

          -  1. The subject underwent a nasal wash/aspirate as part of standard of care testing
             during this study visit.

          -  2. The subject is currently receiving or has received within the past thirty (30) days
             of the study visit an experimental biologic, drug, or device including either
             treatment or therapy.

          -  3. The subject has previously participated in this research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Chappel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chappel Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Rosen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ardmore Family Practice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andre Gvozden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gvozden Pediatrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madhavi Ampajwala</last_name>
    <role>Principal Investigator</role>
    <affiliation>Village Health Partners</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Zissman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Associates of Altamonte Springs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melanie Hoppers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physicians Quality Care of Jackson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimberley Henderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Good Samaritan Minute Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Craig</last_name>
    <phone>+44 (0)7541713932</phone>
    <email>david.craig@lumiradx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raechel Lapel, MPH</last_name>
    <phone>888-445-2333</phone>
    <email>rlapel@toolboxmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Pediatric Associates of Altamonte Springs</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daivd Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edward Zissman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chappel Group</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Chappel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Minute Clinic, Georgia Tech</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gvozden Pediatrics</name>
      <address>
        <city>Millersville</city>
        <state>Maryland</state>
        <zip>21108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andre Gvozden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ardmore Family Practice</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Rosen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physicians Quality Care of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melanie Hoppers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Village Health Partners</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Craig</last_name>
    </contact>
    <contact_backup>
      <email>david.craig@lumiradx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Madhavi Ampajwala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POC</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Antigen</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

